These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 27845337

  • 1. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating.
    Ringel-Kulka T, McRorie J, Ringel Y.
    Am J Gastroenterol; 2017 Jan; 112(1):145-151. PubMed ID: 27845337
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
    Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J.
    Curr Med Res Opin; 2017 Jul; 33(7):1191-1197. PubMed ID: 28166427
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
    Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM.
    Am J Gastroenterol; 2006 Jul; 101(7):1581-90. PubMed ID: 16863564
    [Abstract] [Full Text] [Related]

  • 4. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, Morberg CM.
    Br J Nutr; 2015 Nov 28; 114(10):1638-46. PubMed ID: 26382580
    [Abstract] [Full Text] [Related]

  • 5. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis.
    Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P.
    World J Gastroenterol; 2017 Jan 14; 23(2):336-344. PubMed ID: 28127207
    [Abstract] [Full Text] [Related]

  • 6. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.
    Gastroenterol Clin Biol; 2008 Feb 14; 32(2):147-52. PubMed ID: 18387426
    [Abstract] [Full Text] [Related]

  • 7. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, De Giovanni D, Campanozzi A, Miele E, Staiano A.
    J Clin Gastroenterol; 2017 Jan 14; 51(1):e5-e10. PubMed ID: 27306945
    [Abstract] [Full Text] [Related]

  • 8. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.
    Urgesi R, Casale C, Pistelli R, Rapaccini GL, de Vitis I.
    Eur Rev Med Pharmacol Sci; 2014 Jan 14; 18(9):1344-53. PubMed ID: 24867512
    [Abstract] [Full Text] [Related]

  • 9. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar 14; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

  • 10. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome.
    Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P.
    Dig Liver Dis; 2015 Feb 14; 47(2):119-24. PubMed ID: 25488056
    [Abstract] [Full Text] [Related]

  • 11. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, Verhasselt B, van Vlierberghe H, De Vos M, Raes J, De Looze D.
    Gastroenterology; 2021 Jan 14; 160(1):145-157.e8. PubMed ID: 32681922
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study.
    Sudha MR, Jayanthi N, Aasin M, Dhanashri RD, Anirudh T.
    Benef Microbes; 2018 Jun 15; 9(4):563-572. PubMed ID: 29695183
    [Abstract] [Full Text] [Related]

  • 13. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS.
    Hun L.
    Postgrad Med; 2009 Mar 15; 121(2):119-24. PubMed ID: 19332970
    [Abstract] [Full Text] [Related]

  • 14. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
    Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP.
    BMC Gastroenterol; 2018 May 25; 18(1):71. PubMed ID: 29801486
    [Abstract] [Full Text] [Related]

  • 15. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.
    Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, Patel J, Jadon PS, Pandit A, Dargad RR, Khanna S, Kumar S, Day R.
    Gut Microbes; 2024 May 25; 16(1):2338322. PubMed ID: 38630015
    [Abstract] [Full Text] [Related]

  • 16. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.
    Martoni CJ, Srivastava S, Leyer GJ.
    Nutrients; 2020 Jan 30; 12(2):. PubMed ID: 32019158
    [Abstract] [Full Text] [Related]

  • 17. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Andresen V, Gschossmann J, Layer P.
    Lancet Gastroenterol Hepatol; 2020 Jul 30; 5(7):658-666. PubMed ID: 32277872
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System.
    Chang L, Lacy BE, Moshiree B, Kassebaum A, Abel JL, Hanlon J, Bartolini W, Boinpally R, Bochenek W, Fox SM, Mallick M, Tripp K, Omniewski N, Shea E, Borgstein N.
    Am J Gastroenterol; 2021 Sep 01; 116(9):1929-1937. PubMed ID: 34465695
    [Abstract] [Full Text] [Related]

  • 19. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.
    Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR.
    Neurogastroenterol Motil; 2005 Oct 01; 17(5):687-96. PubMed ID: 16185307
    [Abstract] [Full Text] [Related]

  • 20. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
    O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM.
    Gastroenterology; 2005 Mar 01; 128(3):541-51. PubMed ID: 15765388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.